Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The cadherin 1 (<i>CDH1</i>) gene plays critical roles in the epithelial-mesenchymal transition process, potentially offering us a glimpse into the development of endometrial carcinoma (EC).
|
30405831 |
2018 |
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Finally, six UCEC-related triplets were selected in which the mRNA participates in endometrial carcinoma pathway, such as CDH1 and TP53.
|
28280730 |
2017 |
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Knocking-down Cdh1 in ECA cell lines increased Skp2/Cks1 E3 ligase activity, completely diminished nuclear and cytoplasmic p27, and obviated TGF-β-mediated inhibition of proliferation.
|
26963853 |
2016 |
Endometrial Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The role of WWOX tumor suppressor gene in the regulation of EMT process via regulation of CDH1-ZEB1-VIM expression in endometrial cancer.
|
25892250 |
2015 |
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mice with conditional ablation of Cdh1 and Trp53 (Cdh1(d/d)Trp53(d/d)) clearly demonstrate architectural features characteristic of type II ECs, including focal areas of papillary differentiation, protruding cytoplasm into the lumen (hobnailing) and severe nuclear atypia at 6 months of age.
|
24998851 |
2015 |
Endometrial Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
No associations were noted between promoter hypermethylation of the CDH1 gene and biological features of the endometrial cancer cases.
|
24068440 |
2013 |
Endometrial Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the OCT4 protein in primary human endometriotic stromal cells and human RL95-2 and HEC1A endometrial carcinoma cell lines resulted in decreased levels of E-CADHERIN, the increased expression of the VIMENTIN, TWIST, and SLUG proteins, and an increase in the migration activity of endometrial cells in transwell and wound closure assays.
|
23290742 |
2013 |
Endometrial Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Quantitative methylation studies dismissed CDH1 promoter hypermethylation as the mechanism responsible for this change in gene expression, while immunohistochemistry revealed that the E-cadherin repressor ZEB1 was frequently overexpressed (62%) in undifferentiated endometrial carcinomas.
|
23743934 |
2013 |
Endometrial Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
All E-cadherin repressors (SNAI1, SNAI2 (SLUG), ZEB1, HMGA2, and TWIST1) had a higher expression in endometrioid endometrial carcinomas than in normal endometrium (P < .0001), whereas CDH1 (E-cadherin gene) tended to be lower.
|
21940036 |
2012 |
Endometrial Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Nude mice with xenografted implants of human EC HEC-1-B cells were treated with valproic acid (VPA) and decitabine (DAC) and evaluated for tumor growth, CDH1 and Bcl-2 mRNA levels.
|
22343305 |
2012 |
Endometrial Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
We found that the hypermethylation of CDH1 promoter, which caused low expression of E-cadherin in endometrial cancer, was associated with not only clinicopathological progress of endometrial cancer but also with the overall 5-year clinical survival rate.
|
20874004 |
2011 |
Endometrial Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Methylation of E-cadherin was found only in EC (22.1%).
|
19900189 |
2010 |
Endometrial Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
This is the first report to analyze methylation of the E-cadherin gene promoter of endometrial carcinoma and the evidence suggests that methylation of the E-cadherin gene occurs in association with the acquisition of invasive capacity.
|
12569599 |
2003 |
Endometrial Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Suppression of gap junctional intercellular communication via 5' CpG island methylation in promoter region of E-cadherin gene in endometrial cancer cells.
|
12896902 |
2003 |
Endometrial Carcinoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
CDH1 promoter hypermethylation was found in 21.2% of endometrial carcinomas but was not associated with clinicopathological or immunohistochemical variables.
|
12635138 |
2003 |
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Mutations of the E-cadherin gene in human gynecologic cancers.
|
8075649 |
1994 |
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
Endometrial Carcinoma
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Endometrial Carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|